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Abstract
Aberrant expression of Aurora A kinase has been frequently implicated in many cancers and contributes to chromosome
instability and phosphorylation-mediated ubiquitylation and degradation of p53 for tumorigenesis. Previous studies
showed that p53 is degraded by Kaposi’s sarcoma herpesvirus (KSHV) encoded latency-associated nuclear antigen (LANA)
through its SOCS-box (suppressor of cytokine signaling, LANA
SOCS) motif-mediated recruitment of the EC5S ubiquitin
complex. Here we demonstrate that Aurora A transcriptional expression is upregulated by LANA and markedly elevated in
both Kaposi’s sarcoma tissue and human primary cells infected with KSHV. Moreover, reintroduction of Aurora A
dramatically enhances the binding affinity of p53 with LANA and LANA
SOCS-mediated ubiquitylation of p53 which requires
phosphorylation on Ser215 and Ser315. Small hairpin RNA or a dominant negative mutant of Aurora A kinase efficiently
disrupts LANA-induced p53 ubiquitylation and degradation, and leads to induction of p53 transcriptional and apoptotic
activities. These studies provide new insights into the mechanisms by which LANA can upregulate expression of a cellular
oncogene and simultaneously destabilize the activities of the p53 tumor suppressor in KSHV-associated human cancers.
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Introduction
Kaposi’s sarcoma-associated herpesvirus (KSHV), also named
human herpesvirus 8, is a member of the gamma-herpesviruses
and is associated with Kaposi’s sarcoma (KS), multicentric
Castleman’s disease (MCD) and primary effusion lymphoma
(PEL) [1–4]. Studies have shown that PELs are dependent on
KSHV for survival, as loss of the KSHV genome results in cell
death [5]. These findings demonstrate that KSHV infection can
reprogram cellular gene function and thereby mediate viral
oncogenesis. KSHV is predominantly latent in most cells in
KSHV-associated lesions and during latency only a few viral genes
are expressed. The latency associated nuclear antigen (LANA)
encoded by open reading frame (ORF) 73, is one of the critical
KSHV encoded latent antigens, and is expressed in viral infected
tumor cells of KSHV-associated malignancies [6,7]. LANA plays a
multifunctional role contributing to viral persistence and tumor-
igenesis through targeting DNA replication, chromosome tether-
ing, anti-apoptosis, cell cycle regulatory, and gene regulatory
functions [8–13]. At the gene transcription level, LANA exerts
broad repressive or activation effects by interacting with a number
of transcriptional factors including mSin3A, CBP, RING3, GSK-
3b and p53 for its transcription repression activities [8,14–16], and
E2F, Sp1, RBP-Jk, ATF4, CBP, Id-1, and Ets to drive
transcriptional activation [17–22].
Aurora A, a centrosome-associated Serine/Threonine onco-
genic kinase, was first identified as a human homologue of the
Aurora/Ipl1p kinase family [23]. The human Aurora A gene is
located at chromosomal region 20q13.2 and contains a 1209-bp
open reading frame that encodes 403 amino acids with a
molecular weight of 46 kDa [24]. The promoter of Aurora A
contains three putative binding sites for transcription factors: E2F,
Sp1 and Ets [25]. Aurora A localizes around centrosomes during
interphase and prophase, on the microtubules near spindle poles in
metaphase and the polar microtubles during anaphase & telophase
[26]. Aurora A participates in multiple functions associated with
mitotic events, including centrosome maturation and separation,
bipolar spindle assembly, chromosome alignment and cytokinesis
[27]. Enhanced expression of Aurora A can lead to centrosome
amplification and aneuploidy as a results of incomplete cytokinesis,
which results in either cell death or survival through malignant
transformation in a p53-dependent manner [28,29]. Aberrant
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tumor types and in most human cancer cell lines [24,28,30–32]. A
number of substrates of Aurora kinase A have been identified, such
as TPX2 [33], Eg5 [34], CDC25B [35], p53 [36] and BRCA-1
[37].
Like the aberrant expression of Aurora A, loss of p53 function
also induces similar phenotypes of centrosome amplification and
aneuploidy in cells [38,39]. It is well known that wild type p53 is
able to induce growth arrest or apoptosis when cells are exposed to
stress, and p53 is frequently mutated or deleted in human cancers
[38,39]. As a substrate of Aurora A kinase, p53 can be
phosphorylated on both Ser215 and Ser315 and this leads to
destabilization and inhibition of p53 via the Mdm2-mediated
ubiquitylation and proteasomal degradation pathway [36,40]. In
KSHV latently infected cells, our previous studies have shown that
p53 can be degraded by the cellular EC5S ubiquitin complex-
mediated pathway targeted by the SOCS motif of LANA [41]. In
this study, we further show that the protein levels of Aurora A
kinase is upregulated by LANA, and that elevated Aurora A
induces phosphorylation of p53 which enhances the interaction of
LANA with p53, and promotes LANA-mediated p53 ubiquityla-
tion and degradation, and hence inhibition of p53 transcriptional
and apoptotic activities.
Results
Aurora A expression is upregulated in the LANA-
expressing cells
Aurora A has been shown to aberrantly accumulate and inhibit
p53 function in most cancer cells. To analyze whether LANA-
mediated inhibition of p53 in KSHV latently infected cells is
associated with Aurora A, we first tested the protein levels of
Aurora A in KSHV positive KS tumor samples and KSHV
negative normal tissues by immunohistochemistry assays. The
results showed that Aurora A expression is highly expressed in KS
patient tissue and not in normal tissue (Figure 1A). The
observation from de novo infection of human primary cells with
KSHV in vitro shows that although there was an overall increase of
Aurora A mRNA transcript and protein levels up to 7-days post-
infection, the peak level of Aurora A was at 2-days post-infection
(Figure 1B and C). This strongly indicates that elevated expression
of Aurora A was indeed associated with KSHV infection, and that
the early rapid enhancement of Aurora A expression could be
important for KSHV to establish long term latent infection. To
elucidate the role of LANA on Aurora A expression, LANA in
KSHV-positive BC3 cell line was transiently knocked down by
introduction of small interference RNA specifically against LANA
without interrupting other latent transcripts (supplementary Figure
S1). The levels were monitored by western blot analysis. The
results showed that the protein levels of Aurora A were greatly
decreased once LANA expression was reduced (Figure 2A, left
panel). In addition, a significant reduction in Aurora A transcripts
was observed after LANA was inhibited (Figure 2A, right panel),
supporting the hypothesis that LANA can modulate the
transcriptional activity of Aurora A promoter and so regulate
Aurora A expression. This is further confirmed by the fact that
LANA induces a dose-dependent increase in Aurora expression in
HEK293 cells with transient transfection (Figure 2B). To
determine which phase of cell cycle expressing Aurora A is
affected by LANA, the levels of Aurora A at different cell cycle
phases in the presence or absence of LANA were determined by
flow cytometric analysis. The results showed that LANA
dramatically enhanced Aurora A expression at G1 and S phases
but mildly so at G2/M phase (Figure 2C and D). This indicated
that LANA can play a role in maintaining higher level of Aurora A
at different phases of cell cycle.
LANA upregulates Aurora A transcripts by targeting the
Sp1 cis element within the promoter
Given the modulation of Aurora A expression by LANA, we
constructed a luciferase reporter driven by Aurora A promoter
(position 2527 to +387) (supplementary Figure S2A), and
performed reporter assays in the presence or absence of LANA
in both HEK293 and DG75 cells. The results showed that LANA
dramatically enhanced the transcription level of the Aurora A
promoter when compared to vector control (supplementary Figure
S2B), which was further corroborated by a dose-dependent
induction (supplementary Figure S2C).
A transcription factor analysis and previous studies identified
three cis elements E2F, Sp1 and Ets within the Aurora A promoter
[42]. To define which cis element is critical for LANA to activate
Aurora A transcription, a series of mutants of the Aurora A
promoter driving the luciferase reporter gene were generated and
subjected to reporter assays in HEK 293 cells in the presence or
absence of the LANA. As shown in Figure 3A, in the presence of
LANA, the Aurora A promoter with specific deletions of E2F or
Ets transcription factor-related locus (DE2F or DEts) resulted in a
mild difference in stimulation of Aurora A promoter activity when
compared to the wild type Aurora A promoter (E2F+Sp1+Ets).
However, the Aurora A promoter with deletion of both Sp1 and
Ets elements (DSp1+Ets) or Sp1 alone (DSp1) led to a remarkable
decrease in the promoter activity (Figure 3A). These results
strongly suggested that the Sp1 responsive element within the
Aurora A promoter is a major cis element modulated by LANA.
To further confirm that the Sp1-binding site within the Aurora A
promoter is a major target for LANA, we performed chromatin-
immunoprecipitation assays with Sp1 or E2F specific antibodies
using BC3 cells with or without LANA knockdown. Consistently,
the results showed that Sp1 had a much higher affinity than E2F
when compared to the non-specific IgG control in binding to
Aurora A promoter (Figure 3B). Inhibition of LANA expression
dramatically reduced the association of Sp1 to its cis-acting
element (Figure 3B). This suggests that LANA can enhance
Aurora A transcript levels through targeting of the Sp1 cis-element
within the promoter.
Author Summary
Aurora kinases are evolutionally conserved serine/thero-
nine kinases that regulate cell mitotic progression in
eukaryotic cells. Aurora kinase A, B and C were identified in
mammalian cells. Among them, Aurora A was first known
to regulate genomic instability and tumorigenesis, and is
frequently amplified in multiple human cancers. Aurora-
kinase inhibition has been shown to effectively block cell
growth and induce death of cancer cells. Kaposi’s sarcoma-
associated herpesvirus (KSHV) encoded latency-associated
nuclear antigen (LANA) is essential for KSHV-induced
transformation of primary human B-lymphocytes and
endothelial cells. In this study, we discovered that LANA
remarkably enhances Aurora A production, and that
elevated Aurora A acts as a negative regulator to induce
phosphorylation and LANA-mediated ubiquitylation of
p53. Importantly, inhibition of Aurora A production leads
to cell death of KSHV-positive B lymphoma cells. This study
clearly demonstrates that Aurora A is targeted by an
oncogenic virus for inhibition of p53 function, and is a
potential target for viral associated cancer therapy.
KSHV Upregulates Aurora A
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transcriptional activity
To further determine if Aurora A is important for LANA to
inhibit p53 function, we performed reporter assays in the p53-null
Saos-2 cells by using a luciferase reporter driven by 13 consensus
p53-binding sites. The resultsfrom reporter assays showed that both
LANA and Aurora A individually reduced the transcriptional
activity of p53 (Figure 4A, lane 3 and 4), and co-expression of
Aurora A dramatically enhanced LANA-mediated inhibitory
function of p53 expression (Figure 4A, lane 5). To determine if
Aurora A-associated Mdm2 plays a role in cooperation of Aurora A
with LANA as it relates to inhibition of p53, we also performed
similar reporter assays in both Mdm2
+/+ and Mdm2
2/2 cells. The
results further showed that in the absence or presence of Mdm2,
AuroraAmaintained itsabilitytocollaboratewith LANAinregards
to inhibition of p53 transactivation (Figure 4B and C, lane 1 and 2).
However, compared to wild type Aurora A, the kinase inactive
mutant (KR) of Aurora A can greatly reverse LANA-mediated
inhibition of p53 transactivation (Figure 4B and C, compare lane 2
with 3). This indicates that the KR mutant of Aurora A can act as a
dominantnegativemoleculeand thatthekinaseactivityofAuroraA
is required for LANA -induced repression of p53 transcriptional
activity. Strikingly, in all three cell lines (p53
2/2, p53
2/2Mdm2
2/2
and p53
+/+Mdm2
+/+), we observed that co-expression of wild type
Aurora A but not its KR mutant dramatically reduced the protein
levels of p53 inhibited by LANA (Figure 4A, B and C, lower panels).
Therefore, the kinase activity of Aurora A contributes to LANA-
mediated degradation of p53 and so a reduction in p53
transcriptional activity.
Aurora A enhances LANA
SOCS-mediated ubiquitylation of
p53 by inducing p53 phosphorylation
Our previous work has shown that LANA can recruit the EC5S
ubiquitin complex to degrade p53 [41]. To determine if Aurora A
enhances LANA-mediated p53 proteolytic degradation, we
assessed the stability of p53 in HEK293 cells transfected with
Figure 1. Aurora A expression is up-regulated in KSHV latently infected cells. (A) The protein levels of Aurora A were enhanced in KSHV-
associated KS patient skin tissue. Kaposi’s sarcoma tissue specimens from 3 patients were analyzed for both LANA and Aurora A expression by
immunohistochemistry. A representative sample of Kaposi’s sarcoma patient (middle and right panels) and the adjacent normal tissue (left panel) are
shown. (B) Quantitative real-time PCR analysis of Aurora A and LANA transcripts in PBMC with GFP-KSHV infection. Total RNA was isolated from cells
with GFP-KSHV infection for 0, 1, 2, 4 and 7 days. Real-time PCR was performed as described in Materials and Methods. The relative levels of Aurora A
and LANA transcript were calculated by the cycle threshold (DDCt) values and shown by the fold change compared to mock (day 0). All samples were
tested in triplicate and the calculation of the mean and standard deviation from two separate experiments. The mock cells without or with GFP-KSHV
infection for 4 days were shown on the top. (C) Immunoblotting analysis. Whole cell lysate of human PBMC cells with GFP-KSHV infection for 4 days
or mock, were subjected to immunoblotting with antibodies against LANA, Aurora A and GAPDH. The relative instensity (RI) of Aurora A is quantified
and shown in the figure.
doi:10.1371/journal.ppat.1002566.g001
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different time points. The results consistently showed lower levels
of p53 in cells transfected with Aurora A than in cells transfected
with a control vector (supplementary Figure S3). Treatment with
cycloheximide for 210 min decreased p53 levels by almost 75% in
Aurora A transfected cells compared to about 40% in the control
cells (supplementary Figure S3, lane 4 and 8). Phosphorylation of
p53 by Aurora A results in greater binding affinity with Mdm2
[40]. To determine if active Aurora A kinase enhanced the
interaction of p53 with LANA, we monitored the association of
p53 with LANA in the presence of wild type Aurora A or its
inactive mutant KR by coimmunoprecipitation assays. Substan-
tially more LANA protein was pulled down by p53 in the presence
of wild type Aurora A than in the presence of the mutant control
in both Saos-2 and MEF cell lines (Figure 5A).
To further determine if Aurora A-induced greater binding of
p53 to LANA will result in LANA
SOCS-mediated ubiquitylation of
p53, we performed p53 ubiquitylation assays in MEF cells
expressing different combinations of wild type LANA, mutants
of SOCS-motif deleted mutant LANA (DSOCS), wild type Aurora
A and its mutant KR. The results showed that there is substantially
higher amount of ubiquitylated p53 in cells expressing wild type
Figure 2. Aurora A transcript is dramatically enhanced in a LANA-dependent manner. (A) The level of Aurora A expression was decreased
in BC3 cells with LANA knockdown. Cell lysates from BC3 cells with LANA (shLANA) or control firefly luciferase knockdown (shLuc) were subjected to
immunoblotting against LANA, Aurora A and GAPDH, or total RNA were extracted for RT-PCR analysis. (B) LANA increases endogenous Aurora A
expression in a dose-dependent manner. Fifteen million 293 cells were transiently transfected either with empty vector or increasing amounts of
pA3M-LANA. At 36 hours post-transfection, the cells were harvested, lysed and individually subjected to western blot with antibodies against Aurora
A, LANA and Actin. (C) Cytometric profile of Aurora A expression in HeLa cells in the presence or absence of LANA. HeLa cells transfected with pA3F-
LANA or pA3F vector alone were individually divided and subjected to propidium iodide (PI)-staining cell cycle analysis (inset) combined with anti-
Aurora A (FITC) or normal IgG (FITC) staining. A representative of double staining with the gating percentage of Aurora (IgG) expression at G1, S or
G2/M phase of cell cycle was shown. (D) The relative fold of Aurora expression in each phase of HeLa cells with LANA expression or vector alone from
panel C was presented and normalized by IgG staining control. Data from two repeat experiments.
doi:10.1371/journal.ppat.1002566.g002
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or Aurora A (Figure 5B, compare lane 4 with 2 and 3).
Consistently, mutation of the SOCS motif of LANA, the inactive
form of Aurora A or both led to a dramatic reduction of
ubiquitylated p53 (Figure 5B, compare lane 4 with 5, 6, and 7).
This indicates that LANA
SOCS-mediated ubiquitylation of p53
through the EC5S ubiquitin complex requires the kinase activity of
Aurora A.
Previous studies reported that Aurora A is able to phosphorylate
p53 at Ser215 and Ser315 [36,40]. To determine if LANA-
mediated p53 ubiquitylation is dependent on Aurora A-induced
phosphorylation of p53 on Ser215 or Ser315, we performed
similar ubiquitylation assays by using wild-type, S215A or S315A
variants of p53 with wild-type Aurora A and LANA in MEF cells.
The results showed that compared with wild type p53, less
ubiquitylated p53 appeared in cells expressing S215A, S315A or
the S215A/S315A mutant of p53, and S315A had a greater
impact than S215A (Figure 6A, lane 2 with 3, 4, and 5), suggesting
that both Ser215 and Ser315 are phosphorylated by Aurora A and
in turn facilitates LANA-induced ubiquitylation of p53. To further
confirm that LANA does induce p53 phosphorylation through
Aurora A, we coexpressed p53-FLAG with either LANA or empty
vector in the presence of shAurora A or non-specific shLuc control
in Saos-2 cells, followed by immunoblotting analysis with
antibodies against the Ser315-phosphorylated p53. The results
showed that LANA dramatically enhanced the level of phosphor-
ylated p53 on Ser315 which dependent on Aurora A expression
(Figure 6B, compare lane 2 with 1 and 3). Furthermore, Aurora A-
mediated phosphorylation of p53 is required for LANA induced
p53 ubiquitylation and degradation.
Downmodulation of Aurora A attenuates LANA-
mediated inhibition of p53 apoptotic activity
It has been shown earlier that the increased expression of LANA
can inhibit p53-induced apoptosis in p53-null Saos-2 cells [8]. To
determine if Aurora A cooperation with LANA could affect p53-
mediated apoptosis, Saos-2 cells transiently transfected with
constructs expressing wild-type p53, plus either LANA, Aurora
A or both LANA (WT) and Aurora A (WT or KR) in different
combination, were subjected to cell cycle profile analysis. The
results showed that the percentage of p53-induced apoptosis as
determined by the subG1 population was greatly decreased with
coexpression of LANA and Aurora A (Figure 7A, compare lane 2
with 3, 4 and 5, supplementary Figure S4). However, the
combination of LANA with Aurora A mutant KR or LANA
DSOCS with wild type Aurora A, resulted in a dramatic reversal
of the levels of p53 mediated apoptosis (Figure 7A, compare lane 2
with 6 and 7, supplementary Figure S4). To further confirm that
LANA does require Aurora A to inhibit p53-mediated apoptosis,
we performed colony formation assays by coexpressing p53 with
either wild type LANA or its deleted mutant (DSOCS), or empty
vector in the presence or absence of Aurora A knockdown.
Consistent with the expression level of p53 at 2 day posttransfec-
tion, the results of 3-weeks culture showed that p53 expression
alone dramatically blocks colony formation, and wild type LANA
but not its DSOCS mutant markedly reversed the inhibitory
activities of p53 on colony formation (Figure 7B, compare lane 2
with 3 and 4). In contrast, there was no significant difference
between LANA and p53 coexpression compared to p53 alone,
once the expression of Aurora A was knocked down (Figure 7B,
compare lane 6 with 7 and 8). Unexpectedly, we did observe that
Aurora A knockdown alone remarkably reduced colony formation
even without p53 coexpression (Figure 7B, compare lane 2 with 1).
These suggest that Aurora A is important for LANA to inhibit
p53-induced apoptosis by combining their phosphorylation and
ubiquitylation activities.
Aurora A knockdown enhances p53 stability and
potently induces mitotic arrest and cell apoptosis in PEL
cells
To further investigate the effect of Aurora A on the growth and
survival of KSHV-infected B cells, the Aurora A expression in
BC3 cells was knocked down by lentivirus-mediated shRNA
against Aurora A. Lack of Aurora A expression rescued p53
expression about 3 fold in BC3 cells and greatly induced PARP1
cleavage, compared with BC3 cells transfected with control
Figure 3. The Sp1 cis-acting element is critical for LANA-
mediated enhancement of Aurora A transcription. (A) HEK293
cells were co-transfected full length Aurora A promoter or its mutants
driving reporter plasmid with either pA3M-LANA or pA3M vector. At 24-
hrs post-transfection, cells were harvested and subjected to reporter
assay. The schematic representation of full length Aurora A gene
promoter or its mutants-driven luciferase constructs is shown at the
bottom panel. The results were presented by the RLU (relative luciferase
unit) fold compared to pGL3-basic with vector alone. Data is presented
as means6SD of three independent experiments. (B) ChIP analysis of
endogenous Aurora A promoter in BC3 cells with or without LANA
knockdown. ChIP analysis was conducted using normal mouse IgG, a-
E2F, a-Sp1 agarose, and subjected to PCR analysis using primer F(2400)
and R(260) indicated in A. The results of quantitative real-time PCR are
shown at the bottom panel.
doi:10.1371/journal.ppat.1002566.g003
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low sera resulted in a marked increase of more than 4N DNA con-
tent in the cells, as well as the number of apoptotic cells due to in-
hibition of Aurora A expression (Figure 8B and C). Subsequently,
the results of immunofluorescence analysis revealed that cells with
shRNA against Aurora A exhibited a dramatic alteration in
cellular and nuclear morphology. The cells were enlarged and
exhibited an increased presence of multiple and fragmented nuclei
Figure 4. Coexpression of Aurora A enhances LANA-mediated repression of p53 transcriptional activity which depends on its
kinase activity. Ten million of Saos-2 (A), MEF (B), or 293 (C) cells were co-transfected 3 mg p53 reporter plasmid with construct expressing LANA,
Aurora A (WT or KR) or both. At 24 hr post-transfection, cells were harvested and lysed for luciferase assays. The expression levels of each target
proteins were detected by westernblotting and shown at the bottom panels. b-actin blot was used as loading control.
doi:10.1371/journal.ppat.1002566.g004
Figure 5. The active form of Aurora A kinase enhances LANA
SOCS-mediated ubiquitylation of p53. (A) Active form of Aurora A kinase
enhanced the interaction of p53 with LANA. Saos-2 or MEF cells were co-transfected p53-FLAG with pA3M-LANA plus either vector control, wild type
(WT) Aurora A or its kinase inactive mutant (KR). At 36 hr post-transfection, the cells lysates were immunoprecipitated with anti-FLAG (M2) antibody,
followed by immunoblotting with indicated antibodies. The relative intensity (RI) of p53-interacting LANA was presented by normalization with the
protein amounts of both immunoprecipitated p53 and input LANA. (B) The LANA
SOCS–mediated ubiquitylation of p53 was enhanced by Aurora A
coexpression in a kinase activity-dependent manner. MEF cells were cotransfected with the plasmids expressing HA-Ub and p53-FLAG plus LANA-myc
(WT or DSOCS) and Aurora A-myc (WT or KR). At 36 hr post-transfection with additional 6 hr MG132 treatment before harvest, cell lysates were
analyzed by immunoblotting with as indicated antibodies.
doi:10.1371/journal.ppat.1002566.g005
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seen. Furthermore, the fragmented nuclei were apparent in cells
transduced with shAurora A. The proportion of multinucleated
cells or apoptotic cells was progressively increased once Aurora A
Figure 6. Aurora A-induced phosphorylation of p53 is a target
for LANA
SOCS-mediated ubiquitylation. (A) The Aurora A-induced
phosphorylation on Ser 215 and Ser 315 was critical for LANA-mediated
ubiquitylation of p53. MEF cells were cotransfected with different
combinations of HA-Ub, HA-p53 (WT, S215A, S315A or S215A/S315A),
LANA-myc (WT or DSOCS) and Aurora A-myc (WT or KR) as indicated in
the figure. At 36 hr post-transfection with additional 6 hr MG132
treatment before harvest, cell lysates were analyzed by immunoblotting
with as indicated antibodies. (B) LANA upregulated Aurora A-mediated
phosphorylation of p53. MEF cells were cotransfected p53-FLAG with
either plasmid expressing shAurora A or shLuc in the presence or
absence of LANA-myc as indicated in the figure. At 36 hr post-
transfection with additional 6 hr MG132 treatment before harvest, cell
lysates were analyzed by immunoblotting with specific antibodies. The
knockdown efficiency of shRNA against Aurora A is shown at the
bottom panel.
doi:10.1371/journal.ppat.1002566.g006
Figure 7. Aurora A is important for LANA to inhibit p53-induced
apoptosis.(A)Saos-2cellswerecotransfectedwithdifferentcombination
of plasmids expressing p53-FLAG,LANA-myc (wt or DSOCS), Aurora A-myc
(wt or KR) or empty vectors as indicated in the figure. At 36 hr post-
transfection, cell cycle profiles were analyzed with Flow cytometry. The
percentage of subG1 population cells is presented. (B) Knockdown of
Aurora A blocks LANA-mediated inhibition of p53 suppression function in
colony formation. Saos-2 cells were cotransfected with different combi-
nation of plasmids expressing p53-FLAG, LANA-myc (wt or DSOCS) or
empty vectors in the presence of shAurora A or shluc control as indicated
in figure with number 1 to8. Upperpanel, Immunoblotting analysis ofp53-
FLAG expression at 48-hr posttransfection. Middle panel,ar e p r e s e n t a t i v e
of colony formation after 3-week culture was shown. Lower panel,t h ed a t a
are presented as the average from two independent experiments.
doi:10.1371/journal.ppat.1002566.g007
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Aurora A in KSHV-infected cells was sufficient to induce cell
apoptosis. In addition, the result of Aurora A knockdown led to
dramatic increase of p53 accumulation and subG1 population in
293 cells with KSHV infection but not mock 293 cells (Figure 8F),
further supporting the notion that Aurora A is targeted by KSHV
for inhibition of p53-mediated apoptotic function.
Discussion
We and other groups have previously shown that LANA
downregulates p53-associated pathways in the KSHV latently
infected B lymphoma cells [8,41]. In this study, we aimed to
better understand the mechanism underlying LANA-mediated
suppression of p53, a key protein already known to link with
chromosomal instability and apoptosis. With this in mind, we
performed apoptotic and chromosomal stability gene microarray
analysis by using LANA stable expressing cell line and identified
the Aurora A kinase, a mitotic checkpoint protein as one of the
genes upregulated due to LANA expression. Further studies
showed that expression of Aurora A upregulated by LANA is
mainly through enhancing the binding capacity of transcriptional
factor Sp1 to the Aurora A promoter. The elevated levels of
Aurora A subsequently resulted in phosphorylation of p53 at
Ser215 and Ser315 thus facilitating LANA-mediated ubiquityla-
tion and destabilization of p53 (Figure 9). Therefore, LANA has
a dual function in terms of regulating p53 by: 1) Enhancing
Aurora A kinase expression to phosphorylate p53; and 2)
Recruiting the EC5S ubiquitin complex to induce ubiquitylation
of phosphorylated p53. A previous report showed that increased
expression of Aurora A as a result of genetic mutations increased
the growth and survival of HTLV-1-infected T cells [43]. Our
data provide the first evidence showing that a viral protein can
directly target the oncogenic Aurora A kinase for inhibition of
Figure 8. Downregulation of Aurora A induces cell cycle arrest and apoptosis in PEL cells. (A) Induction of PARP1 cleavage and increased
p53 expression in cells with Aurora A knockdown. Parental BC3 cells and BC3 cells transduced by lentivirus expressing small hairpin against Aurora A
(shA#1, shA#2) or luciferase (shLuc), were exposed to 0.1% sera for 18 hr. Cell lysates were subjected to immunoblotting as indicated antibodies in
the figure. The relative instensity (RI) of p53 protein level is shown. (B) FACS analysis of BC3 cells with or without Aurora knockdown. Aurora A
depletion induced cells with greater than 4N DNA content (Propidium iodide staining). (C) Fold changes in the subG1 population of cells with Aurora
A knockdown, as analyzed by FACS. (D) DAPI staining of representative fields show multinucleation (white arrows), and inset fields show
corresponding photographs to the white rectangles in the upper/lower panels. (E) Quantification of the multinucleated (M) and fragmented nuclei (F)
in BC3 cells with or without Aurora A knockdown. (F) Aurora A knockdown dramatically increased p53 accumulation and subG1 population in KSHV-
infected not uninfected cells. 293 (Mock) and 293-Bac36 (KSHV) cells were individually transduced by lentivirus expressing small hairpin against
Aurora A (shA) and luciferase (shLuc) followed by immunoblotting and subG1 population analysis as described in panels A and C.
doi:10.1371/journal.ppat.1002566.g008
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promoter.
The Aurora A gene is located at chromosome 20q13.2, a region
frequently amplified and over-expressed in a variety of human
tumors and cancer derived cell lines [27,29,44]. However, we did
not observe a consistent difference in levels of Aurora A expression
in KSHV-positive cell lines (BC3, BCBL1, JSC1 and BC1) and in
KSHV negative cell lines (BJAB, Ramos, Loukes and DG75). To
support our hypothesis that KSHV latent infection is directly
associated with the elevated production of Aurora A, the levels of
AuroraA transcripts in humanprimarycells with and without GFP-
tagged KSHV infection were analyzed. Although the increased
pattern of Aurora A (similar pattern for Aurora B, data not shown)
transcripts wasn’t consistently correlated with LANA expression
within 7-days posttransfection, the base levels of Aurora A
transcripts in KSHV-infected cells remained higher than that in
KSHV-uninfected cells. One potential explanation for higher level
of Aurora A mRNA transcripts by 2-days primary infection may be
a benefit to rapidly establish KSHV latent infection. However, the
fact that Aurora A transcript drops following persistent LANA
expressionafter2-daysprimaryinfectioncouldbeanotherbenefitto
the dynamical modulation of Aurora A by LANA and/or other
factors during cell cycle progression. In agreement with the critical
role of LANA on Aurora A expression, the evidence have showed
that increased transient expression of LANA can upregulate Aurora
A expression in a dose-dependent manner, and that knock-down of
LANA in KSHV-positive cell lines decreased both the transcript
and protein levels of Aurora A. In addition, immunohistochemistry
assays further revealed that expression of high levels of Aurora A in
cells from KS tissue is correlated with the presence of LANA in
KSHV-positive cells.
There are at least 20 phosphorylation sites reported for human
p53 [45]. Most of the amino terminal specific phosphorylation
sites prevents Mdm2-mediated ubiquitylation and thus stabilizes
p53 [45]. In contrast, phosphorylation of p53 at its carboxyl
terminus often promotes p53 degradation [45]. For example,
phosphorylation of Ser362/366 by NF-kB induces p53 degrada-
tion [46]. In regards to the effect of Aurora A-induced
phosphorylation of p53, Aurora A is able to induce Mdm2-
mediated p53 degradation by phosphorylating Ser315 [40], and
abrogate the DNA binding and transactivation activity of p53 by
phosphorylating Ser215 not Ser315 [36]. Although this is
somehow controversial, these reports implicate that p53 is a
physiological substrate of Aurora A and that Aurora A may exert
its regulatory functions on p53 through phosphorylation of Ser215
and Ser315 in different cell types. Our data showed that mutation
of p53 at Ser315 dramatically reduced LANA-mediated ubiqui-
tylation of p53 in the presence of Aurora A. However, mutation at
Ser215 also reversed the inhibition of p53 ubiquitylation induced
by LANA. Therefore, the virus has broad control of the kinase
activity of Aurora A in its inhibition of p53 which overcomes the
issue of cell type specificity. In addition, identification of Aurora A
kinase for Ser315 phosphorylation does not rule out possible
involvement of other cell cyclin-dependent kinases, as precedents
for multiple distinct kinases targeting the same phosphorylation
site of p53 (ATM and ATR for Ser15) have been reported [47,48].
Figure 9. A model depicting the role of Aurora A targeted by LANA. In the KSHV latently infected cells, LANA upregulates Aurora A
expression through targeting Sp1-binding site. The elevated Aurora A induced phosphorylation of p53 on Ser 215 and Ser315 which enhanced the
binding affinity of p53 with LANA and promoted LANA
SOCS-mediated ubiquitylation and degradation of p53, and thus inhibited p53 transcriptional
and apoptotic activities. Loss of p53 function and aberrant expression of Aurora A trigger chromosome instability for cell survival and growth.
doi:10.1371/journal.ppat.1002566.g009
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phosphorylatedby AuroraA kinase, we comparedthe effect of wild-
type LANA and mutant LANA (DSOCS) lacking the ability to
ubiquitinate p53 and showed that the ubiquitination activity of
LANA is critical for destabilization of p53 after induction of Aurora
A expression. This suggests that Aurora A phosphorylates p53, thus
enhancing LANA-mediated degradation of p53. Recent reports
show that KSHV targets Mdm2 to deregulate the p53 tumor
suppressor pathway [49,50]. Interestingly, our reporter assay found
that the protein level and transactivation activity of p53 were
dramatically reduced by LANA together with Aurora A in an
Mdm2-independent manner. Phosphorylation of p53 by Aurora A
results in greater binding affinity to Mdm2 and acceleration of its
degradation [40]. However, the possibility exists that Mdm2
contributes to ubiquitylation and degradation of Aurora A-
mediated phosphorylation of p53 in LANA-expressing cells.
Moreover, wild type Aurora A but not its kinase deficient mutant
enhanced interaction of p53 with LANA, and suggests that Aurora
A-induced phosphorylated p53 potentially has a higher affinity for
LANA than the native p53. However, whether Aurora A is directly
involved in a complex which contains p53 and LANA to increase
their ability to interact remains to be further investigated.
Aurora is a subfamily of serine/threonine protein kinases that
plays critical roles in centrosome cycling, spindle assemble,
chromosome segregation and cell division [51,52]. The observa-
tion of growth arrest of cells at the G2-M phase after silencing of
Aurora A kinase in KSHV positive PEL cells, suggests that
degradation of p53 phosphorylated at Ser215 and Ser315, has
physiological relevance in allowing progression of normal cell
proliferation cycle. In regard to our observation that Aurora A
knockdown alone also induces less colony formation in the p53-
null cells, the function of Aurora A on p53 is likely to be the major
but not unique signaling pathway for blocking apoptosis. Our data
also indicated that coexpression of LANA and Aurora A was able
to inhibit p53-mediated apoptosis in the p53-null cell line, Saos-2.
Based on our ubiquitylation assays and protein stability assays,
Aurora A is important for LANA to suppress p53-dependent
apoptosis by phosphorylating p53, followed by its ubiquitination
and degradation. This function of LANA may explain in part why
KSHV latent infection causes oncogenic transformation in
mammalian cells [53].
In summary, Aurora A is a candidate target for inhibition of
tumor growth in a broad range of cancers including pancreatic
and leukemia cells in which it is amplified or induced. Our studies
demonstrates that transcription activation of Aurora A by the viral
protein LANA leads to induced expression of this protein in
KSHV infected cells. Down-regulation of Aurora A by RNA
interference induces cell-cycle arrest, aberrant chromosomal
segregation and apoptosis (about 4-fold higher) in PEL cells,
suggesting that Aurora A could be a promising therapeutic target
in PEL cells.
Materials and Methods
Ethics statement
De-indentified Human peripheral blood mononuclear cells
(PBMCs) were obtained from the University of Pennsylvania
CFAR Immunology Core. The Core maintains an IRB approved
protocol in which Declaration of Helsinki protocols were followed
and each donor gave written, informed consent.
Plasmids, antibodies and cell lines
DNA constructs expressing LANA full length and SOCS-box
mutant in the pA3M vector were described previously [22,41].
The p53 reporter plasmid containing 13 copies of p53-binding
sites at upstream of the luciferase gene was provided by Wafik S.
EI-Deiry (Milton Hersley Medical School, Hersley) [54].
pcDNA4(TO/myc-His)-Aurora A wild type and kinase inactive
K/R mutant were provided by Erich A. Nigg (Max-Planck
Institute of Biochemistry, Martinsried, Germany). HA-p53 WT,
S215A, S315A and S215A/S315A mutant were a kind gift from
Jin Q. Cheng (University of South Florida, Tampa, Florida). The
Aurora A promoter-driven luciferase plasmids pGL3-pAurora A
(E2F+Sp1+Ets) were generated by PCR amplicon inserted into
pGL3 vector with KpnI and BglII digestion. The deleted (DE2F,
DEts, DSp1 or DSp1+Ets) mutants of Aurora A promoter are
derived from pGL3-pAurora A. The monoclonal antibody anti-
myc (9E10) and HA (12CA5) were prepared from hybridoma
cultures. Goat ployclonal antibody against Aurora A (Ark-1, N-20)
was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Mouse monoclonal antibody against FLAG epitope (M2) was
purchased from Sigma-Aldrich Corp. (St. Louis, MO). Rabbit
antibody against phosphorylated p53 (Ser315) was purchased from
Cell Signaling.
The B lymphoma cell lines BC3 (KSHV positive) and DG75
(KSHV negative) were cultured in RPMI 1640 medium
supplemented with 7% fetal bovine serum, 2 mM L-glutamine,
and penicillin-streptomycin (5 U/ml and 5 mg/ml, respectively).
HEK 293, MEF, and Saos-2 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5% fetal
bovine serum, 2 mM L-glutamine, and penicillin-streptomycin
(5 U/ml and 5 mg/ml, respectively). All cell lines were grown at
37uC in a humidified environment supplemented with 5% CO2.
Immunohistochemistry
Slides mounted with sections of paraffin-embedded, archival,
deidentified KS tissue specimens were a generous gift from
Michael Feldman (Department of Pathology and Laboratory
Medicine, Hospital of the University of Pennsylvania, Philadel-
phia, PA). Slides were deparaynized in xylene and rehydrated
through graded alcohols (70, 80, and 100% alcohol; 5 min
each). Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide for 10 min. Following antigen retrieval in
10 mM sodium citrate buffer (pH 6.0), samples were blocked
with 10% normal rabbit/goat serum prior to incubation with
primary antibodies overnight at 4uC. Secondary antibody
(biotinylated anti-rabbit/goat IgG) and streptavidin–peroxidase
conjugate (S-P kit, DAKO) were added according to the
manufacturer’s instructions. Color reaction was developed
using diaminobenzidine chromogen solution (Liquid DAB,
DAKO).
KSHV virion purification and primary infection
The 293/Bac36 (GFP-KSHV) cells were subjected to induction
by TPA and Sodium butyrate for KSHV virion production. After
induction, the supernatant of culture medium was collected and
filtered through 0.45 mm filter, and viral particles were spun down
at 25,000 rpm for 2 h, at 4uC. The concentrated virus was
collected and used for infection or viral DNA quantitation. For
primary infection, 10610
6 PBMC cells were incubated with virus
suspension in 1 ml of RPMI 1640 (10% FBS) medium in the
presence of 5 mg/ml Polybrene (Sigma, Marlborough, MA) and
incubated for 4 hrs at 37uC. Cells were centrifuged for 5 min at
1500 rpm, the supernatant discarded, pelleted cells were resus-
pended in fresh RPMI 1640 (10% FBS) medium in 6 well plates
and cultured at 5% CO2,3 7 uC humidified incubator. The positive
infection was checked by detection of LANA expression.
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Total RNA from cells was extracted using Trizol reagent and
cDNA was made with a Superscript II reverse transcription kit
(Invitrogen, Inc., Carlsbad, CA). The primers for real-time PCR
were as followings: for Aurora A: 59-GGAGAGCTTAAAATTG-
CAGATTTTG-39 and 59-GGCAAACACATACCAAGAGA C-
CT-39; for LANA: 59-CATACGAACTCCAGGTCTGTG-39
and 59-GGTGGAAGAGCC CATAATCT-39; for vCyclinD: 59-
TAATAGAGGCGGGCAATGAG-39 and 59-ACTCCTTT TC-
CCGCCAAGAAC-39; for vFLIP: 59-GTGTAAGAATGTCT-
GTGGTGTGC-39 and 59- GCGGAATGTCTGTTTCGTGC-
39; and for GAPDH: 59-CTCCTCTGACTTCAACAGC G-39
and 59-GC CAAATTCGTTGTCATACCAG-39. The cDNA was
amplified by using 10 ml of Master Mix from the DyNAmo SYBR
green quantitative real-time PCR kit (MJ Research, Inc.), 1 mMo f
each primer, and 2 ml of the cDNA product in a 20-ml total
volume. Thirty cycles of 1 min at 94uC, 30 s at 55uC, and 40 s at
72uC were followed by 10 min at 72uC in an MJ Research
Opticon II thermocycler (MJ Research, Inc., Waltham, MA). A
melting curve analysis was performed to verify the specificities of
the amplified products. The values for the relative levels of change
were calculated by the ‘‘delta delta threshold cycle’’ (DDCT)
method and each sample were tested in triplicates.
RNA interference
Small hairpin RNAs (shRNA) complementary to the C-terminal
(GCTAGGCCACAACACATCT) fragment of LANA as de-
scribed previously [41], or N-terminal (GTCTTGTGTC-
CTTCAAATT) fragment of Aurora A was individually cloned
into pGIPz vector according to the manufacture’s instructions
(Open Biosystem, Inc, Huntsville, AL) to generate shLANA and
shAurora A constructs. pGIPz vector with luciferase target
sequence (shLuc) was used as a control. Fifteen million BC3 cells
were transfected by electroporation (220v, 975 mF, 0.4-cm-gap
cuvette) with 20 mg of shLANA (or shLuc). BC3 knockdown stable
cells were selected and maintained in 4 mg/ml puromycin.
Immunoprecipitation and immunoblotting
Transfected cells were harvested, washed with ice-cold PBS, and
lysed in ice-cold RIPA buffer. Cell debris was removed by
centrifugation at 21,0006 g (10 min and 4uC), and the
supernatant was transferred to a fresh microcentrifuge tube.
Lysates were then precleared by end-over-end rotation with
normal mouse serum and a 1:1 mixture of Protein A and Protein
G-conjugated Sepharose beads (1 hr, 4uC). Beads were spun out,
and the supernatant was transferred to a fresh microcentrifuge
tube. The protein of interest was captured by rotating the
remaining lysate with 1 mg of appropriate antibody overnight at
4uC. Immune complexes were captured with 30 ml of a 1:1
mixture of Protein A and Protein G Sepharose beads, pelleted, and
washed five times with ice-cold RIPA buffer. For immunoblotting
assays, input lysates and immunoprecipitated (IP) complexes were
boiled in Laemmli buffer, fractionated by SDS-PAGE, and
transferred to a 0.45-mm nitrocellulose membrane. The membrane
was then probed with appropriate antibodies followed by
incubation with appropriate infrared-tagged secondary antibodies
and finally was scanned with an Odyssey Infrared scanner (Li-Cor
Biosciences, Lincoln, NE). Densitometric analysis was performed
with the Odyssey scanning software.
Reporter assays
Reporter assay was essentially performed as described previ-
ously [55]. Briefly, the cells were transiently transfected with the
combined plasmids as indicated. The differences in the amounts of
total DNA were normalized with vector control to reach the same
amount of total transfected DNA. At 24 h post-transfection, cells
were harvested and lysed in reporter lysis buffer (Promega Inc.,
Madison, WI). A 40 ml aliquot of the lysate was transferred to a 96-
well plate. Luciferase activity was measured using an LMaxII384
luminometer (Molecular Devices, Sunnyvale, CA) by automati-
cally injecting 25 ml of luciferase substrate into each well and
integrating the luminescence for 20 s post-injection. The results
represent experiments performed in duplicate.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) experiments were
done essentially as previously described with some modifications.
BC3 cells (10610
6) with LANA or control knockdown were cross-
linked with 1.1% (v/v) formaldehyde, 100 mM NaCl, 0.5 mM
EGTA, and 50 mM Tris-HCl (pH 8.0) in growth medium at 37uC
for 10 min, then at 4uC for 50 min. Formaldehyde was quenched
by adding 0.05 vol 2.5 M glycine. Fixed cells were washed with
PBS, incubated for 15 min in 15 ml of 10 mM Tris-HCl (pH 8.0),
10 mM EDTA, 0.5 mM EGTA, and 0.25% (v/v) Triton X-100,
followed by 15 min in 15 ml of 10 mM Tris-HCl (pH 8.0), 1 mM
EDTA, 0.5 mM EGTA, and 200 mM NaCl, and finally sonicated
in 1 ml of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 mM
EGTA, 1% (w/v) SDS plus 1 mM PMSF, 1 mg/ml aprotonin,
leupettin, and pestatin to an average fragment size of 300–500 bp.
20% of solubilized chromatin extracts were saved for input
followed with cross-link reverse step, and the remaining were
clarified by centrifugation at 12,000 g, and diluted to 6 OD260 U/
ml in IP buffer [140 mM NaCl, 1% (w/v) Triton X-100, 0.1% (w/
v) sodium deoxycholate, 1 mM PMSF, 100 mg/ml salmon sperm
DNA, and 100 mg/ml BSA]; preincubated for 1 h at 4uC with
10 ml/ml 50% (v/v) Protein A-agarose (Invitrogen Life Technol-
ogies, Camarillo, CA) with normal mouse/rabbit sera; reconsti-
tuted in PBS, and washed several times in IP buffer. Aliquots
(600 ml) were incubated with 20 mg of each specific antibody for
overnight at 4uC. Immune complexes were separated into bound
and unbound complexes with protein A-agarose and cross-links
were reversed by treatment at 65uC overnight. After treatment
with RNase A and proteinase K, samples were extracted once with
phenol/chloroform, and the DNA was precipitated with 2 volumes
of ethanol. Precipitated DNA was pelleted, washed once with 70%
ethanol, dried, and resuspended in 100 ml of water. The DNA was
analyzed by quantitative PCR with Aurora promoter primers
(sense: 59- TTCGATCGACCAGCTGGTCC GGTTCT -39,
anti-sense: 59- TTCTCGAGCACTTGCTCCCTAAGAAC -39).
In vivo ubiquitylation assay
MEF cells (15610
6) were transfected by electroporation with
appropriate combination of plasmids expressing HA-Ub (5 mg),
p53-FLAG (or HA-p53) (8 mg), Aurora A-myc (8 mg) and LANA-
myc (8 mg). Cells were incubated for 36 hr and pretreated for an
additional 6 hr with 20 mM MG132 (Biomol International) before
harvesting. The extent of ubiquitylation of p53 proteins was
determined by western blot analysis using the FLAG-specific
antibody (M2) or p53 (Do-1) antibody.
Colony formation assay
Ten million of Saos-2 cells were typically transfected using
electroporation with different combinations of expression plasmids
as shown in the text. At 48 hr posttransfection, 1610
4 transfected
cells were cultured in the selection medium (DMEM supplement-
ed with 2 mg/ml puromycin). After 14 days, cells were fixed on the
plates with formaldehyde and stained with 0.1% crystal violet. The
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Odyseesy and counted.
Cell cycle assay
Cells were harvested and washed with ice-cold PBS and fixed in
70% cold ethanol overnight at 4uC. The fixed cells were then
stained with PBS containing 40 mg/ml of propidium iodide
(Sigma, St Louis, MO), 200 mg/ml of RNase A (Sigma) and
0.05% Triton X-100 for 1 h at 4uC in dark. Different cell cycle
phases cells were characterized by using a FACSCalibur (BD
Biosciences, San Joe, CA) and the results were analyzed using the
FlowJo software (Tree star, Ashland, OR). For cytometric
assessment of Aurora A expression profile at G1, S and G2
phase, 10610
6 transfected cells were fixed by 3% paraformaldel-
hyde for 20 min at room temperature, and washed with PBS and
subsequently blocked in 1% BSA with 0.1% Triton X-100,
followed by incubation with 1 mg goat anti-Aurora A antibody
(Ark-1, N-20) or normal IgG serum for overnight at at 4uC. Cells
were washed three times with blocking buffer and exposed to
secondary chicken anti-goat antibody (1:500 dilution) conjugated
with Alexa Fluor 488 for 1 hr at room temperature, followed by
three washes with PBS, and staining with propidium iodide and
RNase A for cell cycle.
Supporting Information
Figure S1 Quantitative analysis of vCyclinD(ORF72),
vFLIP(K13) and LANA(ORF73). Total RNAs from BC3 cells
with transiently LANA knockdown (shLANA) or control firefly
luciferase (shLuc) knockdown were prepared and individually
transcribed to cDNA. The qRT-PCR analysis with the primers for
ORF72, K13 and ORF73 were performed using the Power SYBR
green PCR Master Mix with GAPDH as a control. The relative
quantitation (RQ) of corresponding vCyclinD, vFLIP and LANA
mRNAs was individually presented by dark, light and blank
rectangles. Error bars indicate standard deviations from three
separate experiments. * p.0.05; **p,0.01.
(TIF)
Figure S2 LANA enhanced the transcriptional level of Aurora A
promoter. (A) The schematic representation of the Aurora A gene
promoter-driven luciferase. The putative binding sites for
transcriptional factors E2F, Sp1 and Ets are indicated. The
relative position indicates the distance from the major transcrip-
tional initiation site. (B) HEK293 or DG75 cells cotransfected
pGL3-basic or pGL3-Aurora A with either pA3M-LANA or
empty vector, were harvested at 24 h post-transfection. The cell
lysate were subjected to luciferase reporter assay. The results were
presented by the RLU (relative luciferase unit) fold compared to
pGL3-basic with vector alone. Data is presented as means6SD of
three independent experiments. The immunoblotting (IB) results
of myc-tagged LANA and GAPDH were shown at the bottom
panels. (C) Reporter assay of pGL3- Aurora A promoter co-
transfection with increasing amount (0, 5, 10, 15, 20 mg) of pA3M-
LANA. At 24 h post-transfection, cells were harvested and
subjected to luciferase reporter assay as described in panel B.
The results were presented by the RLU fold compared to pGL3-
Aurora A with empty vector alone.
(TIF)
Figure S3 Coexpression of Aurora A enhanced LANA-mediated
p53 instability. HEK 293 cells were co-transfected pA3M LANA
with Aurora A. At 36 h posttransfection, cells were treated with
40 mg/ml cycloheximide (CHX) for different time points. Then
cells were harvested and lysed for western blot analysis. The
amount of p53 was quantified by band density and is shown
relative to the amount of p53 expressed in the vector-transfected
cells.
(TIF)
Figure S4 Representative data sets showing cell cycle profiles of
Saos-2 cells cotransfected with different combination of plasmids
expressing p53-FLAG, LANA-myc (WT or DSOCS) or Aurora A-
myc (WT or KR) as indicated in the Figure 7A (lanes 1 to 7).
(TIF)
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